These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25312230)

  • 1. A new spin on acquired von Willebrand factor deficiency during continuous-flow left ventricular assist device support.
    Toole JM
    J Thorac Cardiovasc Surg; 2015 Jan; 149(1):289-90. PubMed ID: 25312230
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathologic von Willebrand factor degradation with a left ventricular assist device occurs via two distinct mechanisms: mechanical demolition and enzymatic cleavage.
    Bartoli CR; Restle DJ; Zhang DM; Acker MA; Atluri P
    J Thorac Cardiovasc Surg; 2015 Jan; 149(1):281-9. PubMed ID: 25439775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and In Vitro Evidence That Left Ventricular Assist Device-Induced von Willebrand Factor Degradation Alters Angiogenesis.
    Bartoli CR; Zhang DM; Hennessy-Strahs S; Kang J; Restle DJ; Bermudez C; Atluri P; Acker MA
    Circ Heart Fail; 2018 Sep; 11(9):e004638. PubMed ID: 30354363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preservation of von Willebrand factor multimers and function in patients with an EVAHEART centrifugal-type, continuous-flow left ventricular assist device.
    Ichihara Y; Nishinaka T; Komagamine M; Yamada Y; Yamazaki K
    J Heart Lung Transplant; 2017 Jul; 36(7):814-817. PubMed ID: 28495445
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of ADAMTS-13 by Doxycycline Reduces von Willebrand Factor Degradation During Supraphysiological Shear Stress: Therapeutic Implications for Left Ventricular Assist Device-Associated Bleeding.
    Bartoli CR; Kang J; Restle DJ; Zhang DM; Shabahang C; Acker MA; Atluri P
    JACC Heart Fail; 2015 Nov; 3(11):860-9. PubMed ID: 26454844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device.
    Meyer AL; Malehsa D; Budde U; Bara C; Haverich A; Strueber M
    JACC Heart Fail; 2014 Apr; 2(2):141-5. PubMed ID: 24720921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Willebrand factor disruption and continuous-flow circulatory devices.
    Proudfoot AG; Davidson SJ; Strueber M
    J Heart Lung Transplant; 2017 Nov; 36(11):1155-1163. PubMed ID: 28756118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro comparison of the hemocompatibility of two centrifugal left ventricular assist devices.
    Zayat R; Moza A; Grottke O; Grzanna T; Fechter T; Motomura T; Schmidt-Mewes C; Breuer T; Autschbach R; Rossaint R; Goetzenich A; Bleilevens C
    J Thorac Cardiovasc Surg; 2019 Feb; 157(2):591-599.e4. PubMed ID: 30414772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. von Willebrand factor proteolysis by ADAMTS-13 in patients on left ventricular assist device support.
    Nascimbene A; Hilton T; Konkle BA; Moake JL; Frazier OH; Dong JF
    J Heart Lung Transplant; 2017 Apr; 36(4):477-479. PubMed ID: 28325436
    [No Abstract]   [Full Text] [Related]  

  • 10. Reduced continuous-flow left ventricular assist device speed does not decrease von Willebrand factor degradation.
    Kang J; Zhang DM; Restle DJ; Kallel F; Acker MA; Atluri P; Bartoli CR
    J Thorac Cardiovasc Surg; 2016 Jun; 151(6):1747-1754.e1. PubMed ID: 26971377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time course of acquired von Willebrand disease associated with two types of continuous-flow left ventricular assist devices: HeartMate II and CircuLite Synergy Pocket Micro-pump.
    Goda M; Jacobs S; Rega F; Peerlinck K; Jacquemin M; Droogne W; Vanhaecke J; Van Cleemput J; Van den Bossche K; Meyns B
    J Heart Lung Transplant; 2013 May; 32(5):539-45. PubMed ID: 23570742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left Ventricular Assist Device Design Reduces von Willebrand Factor Degradation: A Comparative Study Between the HeartMate II and the EVAHEART Left Ventricular Assist System.
    Bartoli CR; Kang J; Zhang D; Howard J; Acker M; Atluri P; Motomura T
    Ann Thorac Surg; 2017 Apr; 103(4):1239-1244. PubMed ID: 27717422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II).
    Klovaite J; Gustafsson F; Mortensen SA; Sander K; Nielsen LB
    J Am Coll Cardiol; 2009 Jun; 53(23):2162-7. PubMed ID: 19497443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Models for Translational Investigations of Left Ventricular Assist Device-Associated von Willebrand Factor Degradation.
    Restle DJ; Zhang DM; Hung G; Howard JL; Kallel F; Acker MA; Atluri P; Bartoli CR
    Artif Organs; 2015 Jul; 39(7):569-75. PubMed ID: 25810063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation strategy in a patient on the HeartMate III® left ventricular assist device with acquired von Willebrand syndrome and recurring gastrointestinal bleeding episodes: sometimes less is more.
    Grabner B; Quehenberger P; Schaefer AK; Steinlechner B
    Eur J Cardiothorac Surg; 2020 Apr; 57(4):796-798. PubMed ID: 31177280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired von Willebrand disease in a child with a ventricular assist device.
    Nubret K; Mauriat P; Roubertie F; James C; Tafer N; Ouattara A
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):e30-2. PubMed ID: 23891463
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease.
    Geisen U; Heilmann C; Beyersdorf F; Benk C; Berchtold-Herz M; Schlensak C; Budde U; Zieger B
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):679-84. PubMed ID: 18282712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation.
    Uriel N; Pak SW; Jorde UP; Jude B; Susen S; Vincentelli A; Ennezat PV; Cappleman S; Naka Y; Mancini D
    J Am Coll Cardiol; 2010 Oct; 56(15):1207-13. PubMed ID: 20598466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device.
    Meyer AL; Malehsa D; Bara C; Budde U; Slaughter MS; Haverich A; Strueber M
    Circ Heart Fail; 2010 Nov; 3(6):675-81. PubMed ID: 20739614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired von Willebrand syndrome in a child following Berlin Heart EXCOR Pediatric Ventricular Assist Device implantation: case report and concise literature review.
    Costello JP; Diab YA; Philippe-Auguste M; Jones MB; Shankar V; Friedman KD; Nath DS
    World J Pediatr Congenit Heart Surg; 2014 Oct; 5(4):592-8. PubMed ID: 25324261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.